News
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
18h
Zacks Investment Research on MSNHere's How Lilly's Non-Obesity Drugs are Contributing to Sales GrowthWhile Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for ...
Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...
Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...
These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...
These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...
Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...
A cyberattack on Synnovis has been linked to a patient's death at King's College Hospital, marking a serious hacking ...
These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results